CO5700763A2 - Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra - Google Patents

Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra

Info

Publication number
CO5700763A2
CO5700763A2 CO06068258A CO06068258A CO5700763A2 CO 5700763 A2 CO5700763 A2 CO 5700763A2 CO 06068258 A CO06068258 A CO 06068258A CO 06068258 A CO06068258 A CO 06068258A CO 5700763 A2 CO5700763 A2 CO 5700763A2
Authority
CO
Colombia
Prior art keywords
ona
benzo
derivatives
alkyl
links
Prior art date
Application number
CO06068258A
Other languages
English (en)
Spanish (es)
Inventor
Meng Sui
Shu Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO5700763A2 publication Critical patent/CO5700763A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/181,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO06068258A 2004-01-16 2006-07-13 Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra CO5700763A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53708004P 2004-01-16 2004-01-16

Publications (1)

Publication Number Publication Date
CO5700763A2 true CO5700763A2 (es) 2006-11-30

Family

ID=34794441

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06068258A CO5700763A2 (es) 2004-01-16 2006-07-13 Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra

Country Status (19)

Country Link
US (2) US7196087B2 (https=)
EP (1) EP1708713B1 (https=)
JP (1) JP4533391B2 (https=)
KR (1) KR100843053B1 (https=)
CN (1) CN1909909B (https=)
AR (1) AR047958A1 (https=)
AT (1) ATE388712T1 (https=)
AU (1) AU2005205016B2 (https=)
BR (1) BRPI0506909A (https=)
CA (1) CA2552681A1 (https=)
CO (1) CO5700763A2 (https=)
DE (1) DE602005005298T2 (https=)
ES (1) ES2302174T3 (https=)
IL (1) IL176631A0 (https=)
NO (1) NO20062791L (https=)
RU (1) RU2006129464A (https=)
TW (1) TW200530222A (https=)
WO (1) WO2005067933A1 (https=)
ZA (1) ZA200605434B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102114244A (zh) * 2004-09-30 2011-07-06 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
AU2005316739A1 (en) * 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
BRPI0613430A2 (pt) * 2005-07-13 2011-01-11 Hoffmann La Roche compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―1h―퀴나졸린―2,4―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
CN101600698B (zh) * 2006-09-11 2012-01-11 欧加农股份有限公司;药典有限责任公司 喹唑啉酮和异喹啉酮乙酰胺衍生物
WO2008073958A2 (en) 2006-12-12 2008-06-19 Wyeth Substituted benzothiadiazinedioxide derivatives and methods of their use
MX2010014394A (es) * 2008-06-20 2011-05-19 Rottapharm Spa Derivados de 6-1h-imidazo-quinazolina y quinolinas, nuevos inhibidores de monoamina oxidasa y ligandos del receptor de imidazolina.
EP2328881A1 (en) * 2008-09-08 2011-06-08 F. Hoffmann-La Roche AG 5-substituted benzoxazines
US20110288086A1 (en) 2010-05-21 2011-11-24 Jianqi Li Polycyclic quinazolines, preparation thereof, and use thereof
IL309982A (en) * 2016-11-15 2024-03-01 Univ Temple New modulators of 5-hydroxytryptamine receptor 7 and a method of using them
MX2021013135A (es) 2019-04-29 2021-11-25 Solent Therapeutics Llc Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
JP7696354B2 (ja) * 2019-10-21 2025-06-20 アライリオン インコーポレイテッド 睡眠障害の治療のためのH1および5-HT2A受容体調節物質としての3-(4-(11H-ジベンゾ[b,e][1,4]アゼピン-6-イル)ピペラジン-1-イル)-プロパン酸誘導体および3-(4-(ジベンゾ[b,f][1,4]オキサゼピン/チアゼピン/ジアゼピン-11-イル)ピペラジン-1-イル)-プロパン酸誘導体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642791A (en) 1969-08-13 1972-02-15 Sandoz Ag Morpholino-1-substituted-2(1h)-quinazolinones
JPS5271483A (en) 1975-12-11 1977-06-14 Sumitomo Chem Co Ltd Synthesis of 2(1h)-quinazolinone derivatives
CN1015459B (zh) * 1985-06-06 1992-02-12 田边制药株式会社 喹唑啉酮化合物的制备方法
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
AU6423298A (en) 1997-03-26 1998-10-20 Sumitomo Pharmaceuticals Company, Limited 4-arylmethylene-1,4-dihydro-2h-azine derivatives
DK1028950T3 (da) 1997-10-28 2003-09-01 Warner Lambert Co 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler
WO1999037643A1 (en) * 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
JP2003513075A (ja) * 1999-11-05 2003-04-08 スミスクライン ビーチャム パブリック リミテッド カンパニー 複合5ht1a、5ht1bおよび5ht1d受容体活性を有するイソキノリンおよびキナゾリン誘導体
AU1626001A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors
WO2001044228A2 (fr) 1999-12-14 2001-06-21 Sanofi-Synthelabo Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique
JP2004521892A (ja) * 2000-12-20 2004-07-22 メルク エンド カムパニー インコーポレーテッド (ハロ−ベンゾカルボニル)複素環縮合フェニル系p38キナーゼ阻害剤
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
ES2268113T3 (es) * 2001-06-15 2007-03-16 F. Hoffmann-La Roche Ag Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6.
GB0203804D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
PT1506179E (pt) * 2002-05-13 2006-06-30 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes

Also Published As

Publication number Publication date
WO2005067933A1 (en) 2005-07-28
TW200530222A (en) 2005-09-16
US7365063B2 (en) 2008-04-29
NO20062791L (no) 2006-08-01
JP2007517826A (ja) 2007-07-05
KR100843053B1 (ko) 2008-07-01
CA2552681A1 (en) 2005-07-28
EP1708713A1 (en) 2006-10-11
ATE388712T1 (de) 2008-03-15
JP4533391B2 (ja) 2010-09-01
DE602005005298T2 (de) 2009-03-12
AR047958A1 (es) 2006-03-15
US20050165001A1 (en) 2005-07-28
AU2005205016A1 (en) 2005-07-28
ES2302174T3 (es) 2008-07-01
RU2006129464A (ru) 2008-02-27
KR20060126720A (ko) 2006-12-08
CN1909909A (zh) 2007-02-07
ZA200605434B (en) 2008-02-27
IL176631A0 (en) 2006-10-31
EP1708713B1 (en) 2008-03-12
US20070149510A1 (en) 2007-06-28
AU2005205016B2 (en) 2010-07-15
CN1909909B (zh) 2010-12-15
BRPI0506909A (pt) 2007-05-29
US7196087B2 (en) 2007-03-27
DE602005005298D1 (de) 2008-04-24

Similar Documents

Publication Publication Date Title
ES2515095T3 (es) Derivados de adamantil acetamida como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1
CO6210770A2 (es) Compuestos 2-aril-5-heterociclil-ciclohexan-1, 3 diona y su uso como herbicidas
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
UY31014A1 (es) Derivados de ftalazinona
PE20110397A1 (es) Compuestos que modulan selectivamente el receptor cb2
CO6220907A2 (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
AR076002A1 (es) Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
AR048669A1 (es) Derivados biciclicos de bisamida
TNSN07255A1 (en) Cyclohexylamides as dopamine d3, d2 and 5ht 1a antagonists
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR054814A1 (es) Derivados de piridazina
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR060813A1 (es) Moduladores de mglur5 iii
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR066421A1 (es) Compuestos derivados de piridona
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas

Legal Events

Date Code Title Description
FC Application refused